P
Paul A. Carless
Researcher at University of Newcastle
Publications - 14
Citations - 2814
Paul A. Carless is an academic researcher from University of Newcastle. The author has contributed to research in topics: Blood transfusion & Tranexamic acid. The author has an hindex of 13, co-authored 14 publications receiving 2680 citations. Previous affiliations of Paul A. Carless include University of Ottawa & Mater Health Services.
Papers
More filters
Reference EntryDOI
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
David Henry,Paul A. Carless,Annette J Moxey,Dianne L. O'Connell,Barrie Stokes,Dean Fergusson,Katharine Ker +6 more
TL;DR: Data from the head-to-head trials suggest an advantage of aprotinin over the lysine analogues TXA and EACA in terms of reducing perioperative blood loss, but the differences were small.
Reference EntryDOI
Cell salvage for minimising perioperative allogeneic blood transfusion
TL;DR: The results suggest cell salvage is efficacious in reducing the need for allogeneic red cell transfusion in adult elective cardiac and orthopaedic surgery and the methodological quality of trials was poor.
Journal ArticleDOI
Transfusion triggers: a systematic review of the literature.
Jeffrey L. Carson,Suzanne Hill,Suzanne Hill,Suzanne Hill,Paul A. Carless,Paul A. Carless,Paul A. Carless,Paul C. Hébert,Paul C. Hébert,David Henry,David Henry,David Henry +11 more
TL;DR: The limited published evidence supports the use of restrictive transfusion triggers in patients who are free of serious cardiac disease, however, most of the data on clinical outcomes were generated by a single trial, and need to be tested in further large clinical trials.
Journal ArticleDOI
The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis
TL;DR: Either tranexamic acid or epsilon aminocaproic acid should be recommended to prevent bleeding after cardiac surgery to avoid an increased risk of myocardial infarction with use of aprotinin compared with the lysine analogues.
Journal ArticleDOI
Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion.
David Henry,Paul A. Carless,Annette J Moxey,Dianne L. O'Connell,Katharine Ker,Dean Fergusson +5 more
TL;DR: Although the trials of PAD showed a reduction in the need for allogeneic blood the methodological quality of the trials was poor and the overall transfusion rates (allogeneic and/or autologous) in these trials were high, and were increased by recruitment into the PAD arms of the Trials.